Company news
Biofrontera Inc. news in 2025
Biofrontera Inc.'s news releases, calls and decks from 2025, newest first.
Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio
December 18, 2025
Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities
December 4, 2025
Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT
December 2, 2025
Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update
November 13, 2025
Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M
November 7, 2025
Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025
November 6, 2025
Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG
October 23, 2025
Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
September 26, 2025
Biofrontera Inc. Engages Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program
September 23, 2025
Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extremities, Neck and Trunk
September 16, 2025
Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris
August 25, 2025
Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update
August 13, 2025
Biofrontera Inc. Appoints George Jones as Chief Commercial Officer
August 11, 2025
Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025
August 4, 2025
Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment
June 30, 2025
Biofrontera Inc. is negotiating fundamental changes to its cooperation with Biofrontera AG
June 11, 2025
Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book
June 3, 2025
Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update
May 15, 2025
Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris
May 15, 2025
Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025
May 6, 2025
Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis
May 1, 2025
Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update
March 21, 2025
Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk
March 18, 2025
Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025
March 11, 2025
Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
January 7, 2025